×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GALT – galectin therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GALT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/13
04:28 pm
galt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
1/8
10:00 am
galt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
1/7
10:40 am
galt
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Low
Report
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
1/6
01:15 pm
galt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
1/1
10:00 am
galt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
12/30
12:39 pm
galt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
12/29
09:54 pm
galt
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
Low
Report
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
12/24
07:46 am
galt
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]
Low
Report
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/13
08:40 am
galt
Form 4 GALECTIN THERAPEUTICS For: Jan 05 Filed by: LEWIS JOEL
Medium
Report
Form 4 GALECTIN THERAPEUTICS For: Jan 05 Filed by: LEWIS JOEL
1/12
05:01 pm
galt
Form 8-K GALECTIN THERAPEUTICS For: Jan 10
Low
Report
Form 8-K GALECTIN THERAPEUTICS For: Jan 10
1/6
04:55 pm
galt
Form 4 GALECTIN THERAPEUTICS For: Jan 02 Filed by: LEWIS JOEL
Low
Report
Form 4 GALECTIN THERAPEUTICS For: Jan 02 Filed by: LEWIS JOEL
1/6
04:54 pm
galt
Form 4 GALECTIN THERAPEUTICS For: Jan 02 Filed by: CALLICUTT JACK W
Low
Report
Form 4 GALECTIN THERAPEUTICS For: Jan 02 Filed by: CALLICUTT JACK W
1/6
04:53 pm
galt
Form 4 GALECTIN THERAPEUTICS For: Jan 02 Filed by: Jamil Khurram
Low
Report
Form 4 GALECTIN THERAPEUTICS For: Jan 02 Filed by: Jamil Khurram
1/6
11:10 am
galt
Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.
Medium
Report
Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.
1/5
04:54 pm
galt
Form 144/A GALECTIN THERAPEUTICS Filed by: CALLICUTT JACK W
High
Report
Form 144/A GALECTIN THERAPEUTICS Filed by: CALLICUTT JACK W
1/5
04:08 pm
galt
Form 4 GALECTIN THERAPEUTICS For: Dec 31 Filed by: Jamil Khurram
High
Report
Form 4 GALECTIN THERAPEUTICS For: Dec 31 Filed by: Jamil Khurram
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/10
Form 4 GALECTIN THERAPEUTICS For: Feb 09 Filed by: LEWIS JOEL
11.8%
11/11 Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis 9.8%
8/9 Form S-3 GALECTIN THERAPEUTICS 7.8%
10/23 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. 6.7%
3/20 Form 4 GALECTIN THERAPEUTICS For: Mar 19 Filed by: FREEMAN KEVIN D 6.7%
2/20 Form 8-K GALECTIN THERAPEUTICS For: Feb 19 6.3%
3/16 Form 3 GALECTIN THERAPEUTICS For: Mar 02 Filed by: Boudes Pol F 4.8%
10/17 Form DEF 14A GALECTIN THERAPEUTICS For: Dec 04 3.6%
6/3 Form 4 GALECTIN THERAPEUTICS For: May 29 Filed by: Uihlein Richard E 3.6%
2/4 Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020 2.8%
11/11 Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis 9.8%
8/9 Form S-3 GALECTIN THERAPEUTICS 7.8%
10/23 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. 6.7%
3/20 Form 4 GALECTIN THERAPEUTICS For: Mar 19 Filed by: FREEMAN KEVIN D 6.7%
2/20 Form 8-K GALECTIN THERAPEUTICS For: Feb 19 6.3%
3/16 Form 3 GALECTIN THERAPEUTICS For: Mar 02 Filed by: Boudes Pol F 4.8%
10/17 Form DEF 14A GALECTIN THERAPEUTICS For: Dec 04 3.6%
6/3 Form 4 GALECTIN THERAPEUTICS For: May 29 Filed by: Uihlein Richard E 3.6%
2/4 Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020 2.8%
TOP News Decliners
3/16
Form 8-K GALECTIN THERAPEUTICS For: Mar 16
-17.0%
11/12 Form 10-Q GALECTIN THERAPEUTICS For: Sep 30 -16.9%
4/30 Form 8-K GALECTIN THERAPEUTICS For: Apr 30 -9.0%
4/2 Galectin Therapeutics Update on the Impact of COVID-19 -6.1%
10/24 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
12/4 Form 8-K GALECTIN THERAPEUTICS For: Dec 04 -5.6%
8/13 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
8/9 Q2/2019 6/30/2019 EPS -0.060 ZacksConsensus -0.120 ActVsEst 0.060 - Beat -4.8%
11/15 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -4.3%
7/25 Form 4 GALECTIN THERAPEUTICS For: Jul 15 Filed by: 10X Capital Management, LLC -4.1%
11/12 Form 10-Q GALECTIN THERAPEUTICS For: Sep 30 -16.9%
4/30 Form 8-K GALECTIN THERAPEUTICS For: Apr 30 -9.0%
4/2 Galectin Therapeutics Update on the Impact of COVID-19 -6.1%
10/24 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
12/4 Form 8-K GALECTIN THERAPEUTICS For: Dec 04 -5.6%
8/13 Galectin Therapeutics Inc. (NASDAQ: GALT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
8/9 Q2/2019 6/30/2019 EPS -0.060 ZacksConsensus -0.120 ActVsEst 0.060 - Beat -4.8%
11/15 Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -4.3%
7/25 Form 4 GALECTIN THERAPEUTICS For: Jul 15 Filed by: 10X Capital Management, LLC -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: